Telix and Lightpoint Medical to Collaborate on Radioguided Surgery
Melbourne (Australia) – 23 August 2021. Telix announces collaboration with Lightpoint Medical to explore molecularly targeted radiation and Lightpoint SENSEI® in radioguided surgery (RGS)
Telix is pleased to announce it has signed a strategic collaboration agreement with UK-based Lightpoint Medical (‘Lightpoint’), a leading medical device company developing cancer detection tools for minimally-invasive and robot-assisted surgery. Under the collaboration the two companies will explore how Telix and Lightpoint technologies may be used together for radioguided surgery (RGS) to detect cancer in real-time.
Lightpoint has developed a miniature gamma probe – a device used to detect radiation in patients and guide surgery – which is inserted into a surgical port and can then be controlled by the clinician during the procedure. When used with molecularly-targeted imaging agents, Lightpoint’s device enables the intra-operative detection of cancer in real time, supporting greater precision in the removal of tumours.
Telix and Lightpoint will evaluate the use of Telix’s investigational prostate cancer single photon emission computed tomography (SPECT) imaging agent TLX599-CDx (99mTc-HYNIC-iPSMA) – together with Lightpoint’s SENSEI® flexible laparoscopic gamma probe for intra-operative cancer detection. The ultimate objective of the clinical collaboration is to obtain marketing approval for use of TLX599-CDx in RGS, a new indication for prostate cancer.
Lightpoint Medical CEO, Graeme Smith said, “Surgeons currently have no reliable way to detect cancer intra-operatively, relying on sight or touch during an operation. As a result, cancer may be left behind or healthy tissue needlessly removed. The powerful combination of SENSEI® alongside Telix’s groundbreaking molecularly-targeted imaging agents has the potential to create an extremely precise technique to help surgeons detect cancer that might not otherwise be found during surgery, or conversely, confirm the absence of disease to help surgeons retain healthy, functional tissue. I am extremely excited by the potential of this collaboration to transform surgical outcomes for patients across a range of major cancer types, starting with prostate cancer.”
Telix CEO, Dr. Christian Behrenbruch added, “Bringing molecular imaging into the operating theatre is a key part of our portfolio strategy for urologic oncology, and the combination of Telix and Lightpoint technologies has potential to transform treatment options for patients with cancer. Together with the IRiS Alliance with Mauna Kea, this collaboration helps to reinforce Telix’s position as a leader in developing advanced surgical technologies using highly targeted imaging techniques.”
To read the full ASX disclosure please click here.
To return to Telix’s homepage please click here.